Argent Biopharma Strengthens Foundation with New Equity and Incentive Plans

Argent Biopharma strengthens its financial base and talent retention with a new share issue, employee performance rights, and long-dated options to fuel clinical development.

In a strategic move to bolster its financial structure and retain vital talent, Argent Biopharma has executed a series of capital market and employee incentive actions. The biopharmaceutical firm, which previously operated as MGC Pharmaceuticals, is positioning itself for its next phase of clinical development and potential international expansion.

Employee Retention Takes Center Stage

A core component of the recent strategy involves deepening the alignment between staff and shareholder interests. The company has allocated 2.5 million Performance Rights to its employees. In the research-driven biotechnology sector, securing expert personnel is critical for advancing complex projects, such as the development of the firm's nano-technological drug candidates, CannEpil and CimetrA. These treatments target resistant epilepsy and inflammatory diseases, respectively.

Details of the Capital Raising and Option Issue

Supporting this focus on human capital, Argent Biopharma has also taken steps to enhance its financial flexibility. On March 20, the company issued 1.25 million new ordinary shares. These securities have been admitted for trading on the Australian market without the need for an additional prospectus, a measure designed to support the stock's liquidity. The company emphasized its full compliance with all regulatory requirements in this process.

Concurrently, 2.1 million unlisted options were granted. These options carry an exercise price of AUD 0.20 and are valid until March 2029. Financial instruments of this nature are commonly used to provide future capital-raising potential without causing immediate dilution to existing shareholders.

Building on a Strategic Acquisition

These latest corporate actions follow a period of active growth for the company. Back in November 2025, Argent Biopharma secured funding of up to AUD 11 million to finalize the acquisition of assets from AusCann. This deal was pursued to strengthen the firm's clinical pipeline and its footprint in the European market.

By refining its capital structure and implementing new incentive programs, Argent Biopharma is establishing the administrative groundwork for upcoming clinical milestones. A key strategic objective remains the exploration of a potential secondary listing on a major U.S. exchange, which would further improve access to international investment capital.